Pancragen – 20mg | Pancreatic Tissue Research Compound

Pancragen is a synthetic short-chain peptide bioregulator developed within the Khavinson Cytogen series at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as the pancreas-targeted member of the Cytogen family, joining Cardiogen (cardiac), Cartalax (cartilage), Cortagen (CNS), Crystagen (immune/thymic), and Ovagen (reproductive) as tissue-specific short peptide bioregulators studied for their proposed gene-regulatory mechanisms rather than classical receptor-ligand binding.

Key Research Areas:

• Pancreatic Tissue Gene Regulation — As a Cytogen-class peptide, Pancragen is proposed to interact with nuclear DNA regulatory regions in pancreatic tissue, consistent with the broader Khavinson hypothesis that short peptide bioregulators act by modulating tissue-specific gene expression programs.
• Pancreatic & Endocrine Research — Given the pancreas’s exocrine and endocrine functions, research interest in Pancragen centers on pancreatic cell function, hormone-related signaling, and associated cellular pathways within the broader Cytogen research program.
• Cellular Signaling & Regulation — Pancragen research explores cellular signaling, gene expression, and regulatory pathways specific to pancreatic cell populations in controlled laboratory models.
• Comparative Cytogen Mechanism Research — As with other members of this series, laboratory investigations often study Pancragen alongside sibling Cytogens to understand how tissue-specific targeting is achieved despite structural similarities across the peptide family.

Product Specifications:

• 20mg lyophilized powder per vial
• ≥99% purity via HPLC, third-party COA available
• Store refrigerated (2–8°C) or frozen for long-term storage; protect from light and moisture

For laboratory and research use only. Not intended for human or animal consumption, diagnostic, or therapeutic use. Not a drug, dietary supplement, or cosmetic.